The effects of attenuated rubella virus infection upon cell-mediated immunity of human volunteers were studied. The volunteers received the vaccine either by nose drops or by the subcutaneous route. Changes in cell-mediated immunity in terms of delayed cutaneous sensitivity to recall antigens, phytohemagglutination stimulation, and spontaneous migration inhibitory factor-like activity were studied at various time periods after infection. Spontaneous migration inhibitory factor-like activity was studied on supernatants of the lymphocytes obtained from the volunteers and incubated for 72 h in the absence of any antigens. A significant proportion of the volunteers showed suppression of one or more parameters of cell-mediated immunity tested by week 2 of infection compared to the control; however, there was no correlation between suppression of the various parameters studied. No difference was noticed in the incidence of cell-mediated imnmunity suppression between nose drops and subcutaneous route groups.
Suppression of cell-mediated immunity (CMI) during and after viral infection has been demonstrated in various studies (11, 13, 18, 19) . At present, there is an increased trend to use attenuated live viral vaccines as prophylactic measures, some being administered by the oral or nasopharyngeal route. The effects of various routes of administration of live attenuated virus vaccines on CMI have not been investigated. The present study was designed, therefore, to examine the effects of rubella virus immunization by the subcutaneous (SQ) or nasopharyngeal route upon CMI of volunteers. Changes in CMI in terms of phytohemagglutination (PHA) stimulation, spontaneous lymphokine production, and delayed cutaneous sensitivity (DHS) to common antigens were assessed.
MATE-RIALS AND METHODS
Volunteers. About 350 persons aged 18 to 40 were tested, and 58 seronegative volunteers were identified. Pregnancy in females was ruled out by history and urine testing. Informed consent was obtained after the nature of the procedure had been explained. Volunteers completed a self-evaluation form with regard to signs and symptoms attributable to the vaccine. Immunization. The RA 27/3 strain attenuated rubella virus vaccine (lot no. RU4/21), developed by the Wistar Institute (4, 16) and produced by the Wellcome Research Laboratories, was used for viral challenge. The viral titer was 2 x 103 50% tissue culture infectious doses per ml.
Study groups. Volunteers were randomly divided into two groups depending upon the route of immunization: the first group received the virus by nose drops (ND) (0.25 ml in each nostril) with the subject's head hyperextended; the second group received 0.5 ml of the virus by SQ injection in the usual manner. Seropositive volunteers were also included in the study to serve as controls. The CMI responses in volunteers in these groups before and after immunization were compared.
Lymphocyte culture. Venous blood was drawn into a heparinized (phenol-free) syringe, and erythrocytes were allowed to settle at 27 C. The leucocyterich supernatant was transferred to a glass container with an equal volume of medium and incubated to remove granulocytes. The nonadherent cells were then washed. One-half milliliter of suspension per tube was distributed into Falcon no. 2063 tubes. After the addition of 1 Al of PHA-P (Difco) to the appropriate tubes, all tubes were incubated at 37 C in 50% CO2 in air for 48 h. Radioactive thymidine (1.0 ,ICi/tube) was added, and the tubes were incubated for another 24 h. The cells were then washed once each in saline, cold 5% trichloroacetic acid, and methanol. After being dried overnight the precipitates were dissolved in 0.3 ml of NCS (New England Nuclear) and incubated in the dark for 1 h at 40 C. The solubilized precipitates were added to a scintillation mixture L5 g of 2,5-diphenyloxazole plus 150 mg of dimethyl 1,4- Specimens. Blood was collected prior to 10, 21, and 28 days after virus infection.
Antibody determination. All antibody determinations were done by the hemagglutination inhibition technique as previously described (4).
RESULTS
Age, sex and preimmunization antibody titers in volunteers of the study are shown in Table 1 . Fifty-eight seronegative volunteers and nine seropositive controls were included; 73% were young adult females. In addition, 13 volunteers were included who received placebo instead of the vaccine. They were tested for the various parameters of CMI simultaneously with the vaccinees.
Effects of attenuated rubella vaccine on the delayed skin reactivity to common recall antigens are shown in Table 2 . The data represent the reactivity in terms of DHS to which an individual showed the highest degree of sensitivity. A 50% decrease in DHS with recall antigen was considered significant. No significant difference was observed between ND and SQ groups with regard to DHS depression. Nine volunteers (combined ND and SQ) demonstrated evidence of depressed DHS, whereas only one in the control groups (the seropositive and placebo groups) showed such evidence of decreased skin reactivity. This one volunteer had a low pre-existing antibody level (titer of 1:10) . When compared to the controls (1 positive/22 total), the incidence of depressed DHS (9 positive/21 total) in the vaccinees is statistically significant (P < 0.01).
The effects of the attenuated rubella virus immunization on the lymphocyte PHA response is shown in Table 3 . The ratio of uptake of thymidine by the stimulated culture to the uptake of a simultaneously incubated unstimulated culture was calculated as the stimulation ratio. A decrease in the stimulation ratio by 80% is considered significant. Ten out of nineteen vaccinees (combined ND and SQ groups) tested showed evidence of a suppressed PHA stimulation ratio. None of the controls (combined seropositive and placebo) exhibited such depression of the stimulation ratio. The difference between the control and the test group in the incidence of depression of the stimulation ratio is statistically significant (P < 0.02).
There was no significant difference between the ND and SQ groups.
The spontaneous MIF-like activity produced by lymphocytes from vaccinees is shown in Table 4 . Only three volunteers were tested in the control group, and their lymphocytes did not produce MIF. However, nine vaccinees out of eleven tested demonstrated such activity. There was no difference observed between ND and SQ groups.
Ninety percent of the vaccinees without preexisting antibody responded with a fourfold or greater rise in rubella antibody. There was no significant difference in the geometric mean titer of hemagglutination inhibition antibody in vaccinees in the ND and SQ groups. No significant rise in antibody levels was observed in controls having pre-existing antibody.
There was no correlation observed between the various test systems used to measure suppression of CMI. That is, in a single individual, depression of DHS did not necessarily accompany suppression of either PHA stimulation or production of spontaneous MIF-like activity.
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cine (RA 27/3) on various parameters of CMI in volunteers. Recently, there has been a surge of information on the incidence of suppression of CMI in various viral infections (11, 13, 18, 19) .
Recent evidence also indicates that infection
with attenuated viral vaccines may induce temporary immunosuppression. This has been shown with measles (1, 8, 14) , smallpox (10) , mumps (13), yellow fever (3), polio (2), and influenza vaccines (19 The data obtained in this study indicated that an attenuated rubella vaccine induces transient suppression of CMI. In most volunteers the suppression lasted until week 4 after challenge, but in all volunteers the suppression returned to normal by week 6. All three parameters studies, i.e., DHS to recall antigens, lymphocyte stimulation by PHA, and spontaneous production of MIF-like activity, were abnormal. Preliminary studies on the physicochemical characteristics of this activity (Cusumano et al., submitted for publication) indicated that it resembles human MIF activity as described by others (20 (19) indicated that influenza patients' lymphocytes had a normal PHA response at a time when they were showing skin anergy. This dissociation has also been noted in disease states, such as chronic mucocutaneous candidiasis (12) and sarcoidosis (6) .
It is of interest to compare these data with the results recently published by Munyer et In all of these studies, B cell function has remained intact. For example, in a recent report, Kantzler et al. (11) showed that 12 of 21 individuals who were infected with the attenuated or the virulent influenza virus had depression of T cell functions, but there was no evidence of suppression of B cell functions. This was assessed by measuring the serum antibody to an unrelated antigen before, during and after influenza infection. In the present study, the observation that the rubella-specific antibody reached its peak titer at a time when there was a significant degree of anergy in the vaccinees (2 to 3 weeks after infection) implies that the functional capacity of the B cells and the T cell "helper" function are retained. The significance of the suppression of CMI noted in this and other studies is that it might have implications with regard to the development of malignancy (7) and stimulation of latent infections (21) and is a consideration in the development of attenuated viral vaccines.
